We first evaluated the ability of PP-13 to inhibit growth of human NSCLC cell lines (H358, H322, A549, H1975, H3255, H1650, PC9 and NCI-H460) harbouring various forms of TP53, KRAS and EGFR status (Supplementary Fig. S1). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.